Immunotherapy bowel cancer drug works for 100% of patients – researchers
Jemperli – also called dostarlimab – from GSK showed ‘unprecedented results’, the firm said, with no evidence of disease in all patients treated.
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.
Jemperli (also called dostarlimab) from GSK showed “unprecedented results”, the firm said, with no evidence of disease in all patients treated.
Everyone on the drug had locally advanced mismatch repair deficient (dMMR) rectal cancer, a form of bowel cancer, according to data presented at the American Society of Clinical Oncology (ASCO) conference in Chicago.
Jemperli is already approved on the NHS for women with some types of advanced or recurrent womb cancer.
The data showing no evidence of disease in 42 patients is remarkable
The data showed all 42 patients in a trial led by Memorial Sloan Kettering Cancer Centre in the US had a complete response to treatment, with no evidence of tumours on scans.
The first 24 patients have been followed up so far for 26.3 months on average.
Studies suggest (dMMR) rectal cancer accounts for 5-10% of all rectal cancers.
Hesham Abdullah, a senior vice president at GSK, said: “The data showing no evidence of disease in 42 patients is remarkable.
“These results bring us one step closer to understanding the potential of dostarlimab in this curative-intent setting for patients with dMMR locally advanced rectal cancer.
“We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies.”
The current standard of care for patients with this type of cancer is chemotherapy plus radiation, followed by surgery.
Andrea Cercek, principal investigator for the phase II study, said the new treatment showed “durable complete tumour regression without the need for life-altering treatment” such as chemotherapy and surgery.
She added: “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about thepotential of dostarlimab in these patients.”
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.